Open links in new tab
  1. https://www.eisai.com/news
    News Release：2024 | Eisai Co., Ltd.
    Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzhei…
    Notification of Ransomware Incident
    Eisai Co., Ltd. announced today that the Eisai Group became aware of a ranso…
    Lecanemab-Irmb
    For Print; July 7, 2023; Tokyo and CAMBRIDGE, Mass., July 6, 2023 – Ei…
    Eisai Transfers All Future Economic Rights for Elacestrant, a Selective Estrogen Receptor Degrader, to DRI Healthcare
    Eisai's news release Eisai TRANSFERS ALL FUTURE ECONOMIC RIGHTS F…
    VHA
    Eisai's news release U.S. VETERANS’ HEALTH ADMINISTRATION (VHA) ... …
    Organizational Reform and Changes of Corporate Officers
    Eisai's news release ORGANIZATIONAL REFORM AND CHANGES OF CORPO…
    Eisai Co., Ltd.｜A Human Health Care Company
    Eisai NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRU…
    FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eis…
    FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease. Accelerated Approval is based on Phase 2 data showing a reduction i…
    https://www.eisai.com/news/2023/news2023…
    Did Eisai request a re-examination of the previous negative opinion?
    Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024.
    markets.businessinsider.com
    Feedback
     
  2. eisai.com
    https://www.eisai.com/news/2023/news…

    FDA Approves LEQEMBI™ (lecanemab-irmb) Under the …

    Jan 7, 2023 · FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease. Accelerated Approval is based on Phase 2 data showing a reduction in …

  3. eisai.com
    https://www.eisai.com/news/2022/news…

    EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE …

    Nov 30, 2022 · Eisai’s Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early AD (lecanemab group: 898 placebo group: 897) at 235 sites in North …

  4. NBC News
    https://www.nbcnews.com/health/health-news/leqembi...

    New Alzheimer’s drug Leqembi is granted full FDA approval - NBC …

  6. Eisai Newsroom
    https://media-us.eisai.com/2024-07-30-…

    Eisai and Biogen shared LEQEMBI study results at AAIC …

    Jul 30, 2024 · SOURCE Eisai Co., Ltd. Eisai and Biogen presented LEQEMBI findings from the Clarity AD Phase 3 study, showing significant reductions in cognitive decline and functional improvements.

  7. Eisai Newsroom
    https://media-us.eisai.com/2023-10-25-EISAI...

    EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB ... - Eisai …

  8. People also ask
    Why did Eisai lower its sales forecast for leqembi (lecanemab)?
    Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US. The Japanese pharma expects its lead product co-developed with Biogen to generate $280m (Y42.5bn) in the second half of its 2024 fiscal year, down approximately $90m from the original $370m figure.

    Eisai lowers Leqembi revenue forecast after rocky entry to market

    finance.yahoo.com
    Why did Eisai's shares open 0.92% higher?
    Shares in the company opened 0.92% higher than the previous market close due to strong overall year-over-year revenue and gross profit, both up 103%. Revealing the company’s Q2 results on 8 November, Eisai’s CEO Haruo Naito highlighted a delay in the progression of sales results in the US as a key factor for Leqembi’s adjusted forecast.

    Eisai lowers Leqembi revenue forecast after rocky entry to market

    finance.yahoo.com
    Did Eisai request a re-examination of the previous negative opinion?
    Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024.

    Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’…

    markets.businessinsider.com
    Why was Eisai's Q2 forecast delayed?
    Revealing the company’s Q2 results on 8 November, Eisai’s CEO Haruo Naito highlighted a delay in the progression of sales results in the US as a key factor for Leqembi’s adjusted forecast. Eisai expects a 153% sales growth of the drug in the US from the first half of the fiscal year to the next, compared to a 184% increase in Japan.

    Eisai lowers Leqembi revenue forecast after rocky entry to market

    finance.yahoo.com
    Did Eisai receive a positive opinion on lecanemab in early Alzheimer's disease?
    Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease PR Newswire Thu, Nov 14, 2024, 10:29 AM12 min read In This Article: BIIB

    Eisai Receives Positive Opinion from the CHMP in the European Union f…

    finance.yahoo.com
    Why is Eisai incorporating decentralised elements into its Alzheimer's trials?
    Shobha Dhadda, Eisai’s chief clinical science & operations officer explains that the company has been incorporating decentralised elements into its Alzheimer’s trials to gain granular insights into disease progression and patient responses.

    How decentralisation can fill the gaps in Alzheimer’s research

    msn.com
    Feedback
  9. Eisai Newsroom
    https://media-us.eisai.com/2024-11-14-Eisai...

    Eisai Receives Positive Opinion from the CHMP in the European …

  10. Eisai Inc.
    https://us.eisai.com/press-releases/leqembi...

    LEQEMBI® Intravenous Infusion (Lecanemab) Approved ... - Eisai …

  11. Reuters
    https://www.reuters.com/business/healthc…

    US FDA grants standard approval of Eisai/Biogen …

    LOS ANGELES, July 6 (Reuters) - Eisai (4523.T) and Biogen's (BIIB.O) Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer's...

  12. Eisai Inc.
    https://us.eisai.com/media-center

    Media center - recent news, blogs, and articles | Eisai US

    Oct 30, 2024 · Eisai's media center is where you’ll find breaking news, press releases, as well as blogs and articles about the company, our people, and our innovations.

  14. Some results have been removed